Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Fermin Orgambide

Biomind Begins Clinical Trial For Inhaled DMT Analog Substance To Treat Depression

Biomind Labs (OTCQB:BMNDF) has begun administering its proprietary second-generation psychedelic, BMND01, in a Phase 1/2a clinical trial for treatment-resistant depression (TRD).

The company administered the first subject with the DMT analog to evaluate the safety, pharmacokinetics, behavioral and brain effects of the molecule through inhalation. The team in charge of the study is led by Dr. Dráulio Araújo, Biomind’s scientific and clinical advisor.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.